Why The Next Era Of Biomanufacturing Will Be Won By Intelligence, Not Size

InnovationWhy The Next Era Of Biomanufacturing Will Be Won By Intelligence, Not SizeByHamid Noori,Forbes Councils Member.for Forbes Technology CouncilCOUNCIL POSTExpertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. | Membership (fee-based)May 28, 2026, 07:00am EDTDr. Hamid Noori is the CEO of The Cultivated B. As a scholar, he conducted his work at Princeton, MIT, Max Planck Society and IHES. gettyTalk to anyone who has spent time on a biomanufacturing floor of a pharmaceutical company, and you will eventually hear some variation of the same story. A run went sideways, but not because of a lack of skill or oversight. By the time the offline assay confirmed what the cells were doing, hours had passed, and the batch was unrecoverable. Several members of my own team have lived through that exact scenario inside large biopharma and CDMO operations. Based on my observations across the industry, compound manufacturers report batch failure rates of roughly 5% to 10% on average for biologics and ingredient production, costing billions of dollars annually. Even individual failed batches can sometimes carry losses in the tens of millions. And the consequences ripple beyond any single manufacturer: In 2020, the FDA reported that 62% of all drug shortages were caused by manufacturing and product quality problems, resulting in supply disruptions.These numbers point to something the industry has tolerated for too long. The bioreactor—the core technology powering pharmaceuticals, biologics, food and advanced materials—still operates, in most facilities, as a black box.For decades, the industry's instinct in response to variability and yield pressure has been to scale up: bigger facilities, bigger tanks and more redundant capacity. That playbook produced real gains, but it is reaching its limits. Adding another 20,000-liter tank does not tell you what is happening inside the one you already have. The next decade of biomanu...